The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2024
DOI: 10.1039/d3cs00673e
|View full text |Cite
|
Sign up to set email alerts
|

Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications

Xianbo Wu,
Yuqing Li,
Mei Wen
et al.

Abstract: This review discusses the structures and engineering strategies of nanocatalysts, highlighting their underlying mechanisms and applications in cancer immunotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 489 publications
0
0
0
Order By: Relevance
“…[ 1 , 2 , 3 ] Fortunately, the focus of multidisciplinary deep crossover is to design and construct novel biomaterial‐based cancer treatment strategies in preclinical settings, alleviating or even solving the shortcomings of traditional treatment strategies. [ 4 , 5 , 6 , 7 ] Sonodynamic therapy (SDT) assisted by sonosensitizers stands out for its noninvasiveness, desired biological tolerability, and high tissue penetration depth. [ 8 , 9 , 10 ] Notably, several concurrent clinical trials (NCT05362409; NCT05580328) are evaluating the antitumor efficacy of sonosensitizer‐mediated SDT, either through monotherapy or synergistic treatment, signifying the substantial clinical promise of SDT.…”
Section: Introductionmentioning
confidence: 99%
“…[ 1 , 2 , 3 ] Fortunately, the focus of multidisciplinary deep crossover is to design and construct novel biomaterial‐based cancer treatment strategies in preclinical settings, alleviating or even solving the shortcomings of traditional treatment strategies. [ 4 , 5 , 6 , 7 ] Sonodynamic therapy (SDT) assisted by sonosensitizers stands out for its noninvasiveness, desired biological tolerability, and high tissue penetration depth. [ 8 , 9 , 10 ] Notably, several concurrent clinical trials (NCT05362409; NCT05580328) are evaluating the antitumor efficacy of sonosensitizer‐mediated SDT, either through monotherapy or synergistic treatment, signifying the substantial clinical promise of SDT.…”
Section: Introductionmentioning
confidence: 99%